$7.37
0[0.00%]
At close: Apr 18
$7.37
0[0.00%]
After Hours: 4:20PM EDT
Tango Therapeutics
(NASDAQ:TNGX)Tango Therapeutics Stock (NASDAQ:TNGX), Analyst Ratings, Price Targets, Predictions
Tango Therapeutics Inc has a consensus price target of $15.88, established from looking at the 13 latest analyst ratings. The last 3 analyst ratings were released from Cantor Fitzgerald, HC Wainwright & Co., and Piper Sandler on April 4, 2024, March 20, 2024, and February 12, 2024. With an average price target of $11.67 between Cantor Fitzgerald, HC Wainwright & Co., and Piper Sandler, there's an implied 58.30% upside for Tango Therapeutics Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Cantor Fitzgerald
HC Wainwright & Co.
Piper Sandler
B. Riley Securities
Wedbush
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Tango Therapeutics
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/04/2024 | TNGX | Buy Now | Tango Therapeutics | $7.37 | — | Cantor Fitzgerald | Eric Schmidt | — | Initiates | → Overweight | Get Alert |
| 03/20/2024 | TNGX | Buy Now | Tango Therapeutics | $7.37 | 130.66% | HC Wainwright & Co. | Robert Burns | $16 → $17 | Maintains | Buy | Get Alert |
| 02/12/2024 | TNGX | Buy Now | Tango Therapeutics | $7.37 | 144.23% | Piper Sandler | Joseph Catanzaro | → $18 | Initiates | → Overweight | Get Alert |
| 12/08/2023 | TNGX | Buy Now | Tango Therapeutics | $7.37 | 117.1% | B. Riley Securities | Yuan Zhi | → $16 | Initiates | → Buy | Get Alert |
| 08/11/2023 | TNGX | Buy Now | Tango Therapeutics | $7.37 | 117.1% | HC Wainwright & Co. | Robert Burns | $11 → $16 | Maintains | Buy | Get Alert |
| 08/08/2023 | TNGX | Buy Now | Tango Therapeutics | $7.37 | 49.25% | HC Wainwright & Co. | Robert Burns | → $11 | Reiterates | Buy → Buy | Get Alert |
| 05/10/2023 | TNGX | Buy Now | Tango Therapeutics | $7.37 | 144.23% | Wedbush | Robert Driscoll | → $18 | Reiterates | → Outperform | Get Alert |
| 03/28/2023 | TNGX | Buy Now | Tango Therapeutics | $7.37 | 49.25% | HC Wainwright & Co. | Robert Burns | $10 → $11 | Maintains | Buy | Get Alert |
| 10/20/2022 | TNGX | Buy Now | Tango Therapeutics | $7.37 | 35.69% | HC Wainwright & Co. | Robert Burns | → $10 | Initiates | → Buy | Get Alert |
| 09/20/2021 | TNGX | Buy Now | Tango Therapeutics | $7.37 | 239.21% | SVB Leerink | Andrew Berens | — | Initiates | → Outperform | Get Alert |
| 09/07/2021 | TNGX | Buy Now | Tango Therapeutics | $7.37 | 171.37% | Wedbush | Robert Driscoll | — | Initiates | → Outperform | Get Alert |
| 09/07/2021 | TNGX | Buy Now | Tango Therapeutics | $7.37 | 117.1% | Guggenheim | — | — | Initiates | → Buy | Get Alert |
| 09/07/2021 | TNGX | Buy Now | Tango Therapeutics | $7.37 | 130.66% | Goldman Sachs | Chris Shibutani | — | Initiates | → Buy | Get Alert |
FAQ
What is the target price for Tango Therapeutics (TNGX)?
The latest price target for Tango Therapeutics (NASDAQ: TNGX) was reported by Cantor Fitzgerald on April 4, 2024. The analyst firm set a price target for $0.00 expecting TNGX to fall to within 12 months (a possible -100.00% downside). 7 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Tango Therapeutics (TNGX)?
The latest analyst rating for Tango Therapeutics (NASDAQ: TNGX) was provided by Cantor Fitzgerald, and Tango Therapeutics initiated their overweight rating.
When was the last upgrade for Tango Therapeutics (TNGX)?
There is no last upgrade for Tango Therapeutics.
When was the last downgrade for Tango Therapeutics (TNGX)?
There is no last downgrade for Tango Therapeutics.
When is the next analyst rating going to be posted or updated for Tango Therapeutics (TNGX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Tango Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Tango Therapeutics was filed on April 4, 2024 so you should expect the next rating to be made available sometime around April 4, 2025.
Is the Analyst Rating Tango Therapeutics (TNGX) correct?
While ratings are subjective and will change, the latest Tango Therapeutics (TNGX) rating was a initiated with a price target of $0.00 to $0.00. The current price Tango Therapeutics (TNGX) is trading at is $7.37, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.